Phillip MD - Veracyte Chief Officer

Veracyte Management Efficiency

The company has return on total asset (ROA) of 0.0107 % which means that it generated a profit of $0.0107 on every $100 spent on assets. This is way below average. Veracyte's management efficiency ratios could be used to measure how well Veracyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.09 in 2024. At this time, Veracyte's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 1.2 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 1.2 M in 2024.

Similar Executives

The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Veracyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 761 people. Veracyte (VCYT) is traded on NASDAQ Exchange in USA. It is located in 6000 Shoreline Court, South San Francisco, CA, United States, 94080 and employs 815 people. Veracyte is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Veracyte Leadership Team

Veracyte Stock Performance Indicators

Additional Tools for Veracyte Stock Analysis